SynthesisImmunologic research2025
Polymorphisms in STAT4 and PTPRC genes in rheumatoid arthritis: a Brazilian study and meta-analysis of susceptibility and TNFi response.
Synthesis in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic Association Between BTN3A1 Polymorphisms and the Risk of Rheumatoid Arthritis in a Chinese Population.International journal of rheumatic diseases · 2026Article
- Precision medicine in rheumatoid arthritis: advances and clinical applications of multi-omics biomarkers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Genetic factors play a key role in its pathogenesis and may also influence therapeutic response. This study aimed to investigate the association of the STAT4 rs7574865-T and PTPRC rs10919563-A polymorphisms with RA susceptibility and response to TNF inhibitor (TNFi) treatment in a Brazilian population. A case-control study was conducted including 295 RA patients treated with TNFi and 303 healthy controls. Genotyping of rs7574865 (STAT4) and rs10919563 (PTPRC) was performed. Associations with RA susceptibility, TNFi treatment response, and therapy discontinuation due to adverse events were evaluated under different genetic models. A meta-analysis integrating our results with previously published studies was also conducted. The rs7574865-T allele was associated with increased RA risk (OR: 1.43; 95% CI: 1.03-1.99; p = 0.036; p perm = 0.042), reduced response to TNFi (OR: 0.28; 95% CI: 0.07-0.99; p = 0.047; p perm = 0.058), and higher likelihood of treatment discontinuation due to adverse events (OR: 1.89; 95% CI: 1.01-3.58; p = 0.047;p perm = 0.034). After permutation-based correction (1,000 iterations), all associations remained consistent except for the recessive model in TNFi response, which became non-significant (p_perm = 0.058). The meta-analysis confirmed a 40% increased RA susceptibility in T allele carriers. No significant association was observed for rs10919563-A regarding RA risk or TNFi response. A genetic interaction between STAT4 (G/T) and PTPRC (A/A, p = 0.008; G/G, p = 0.017) genotypes was observed, suggesting an increased RA risk for these genotype combinations, without significant correlation with TNFi treatment outcomes. Our findings reinforce the role of STAT4 rs7574865-T in RA susceptibility and TNFi treatment outcomes and highlight the potential for personalized therapeutic strategies based on genetic profiles.
Indexed as
Identifiers
41231349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.